Blockade of transforming growth factor-beta (TGFβ) signaling inhibits osteoblastic tumorigenesis by a novel human prostate cancer cell line

Sweta Mishra, Yuping Tang, Long Wang, Linda Degraffenried, I. Tien Yeh, Sherry Werner, Dean Troyer, John A III Copland, Lu Zhe Sun

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

BACKGROUND The skeleton is the most common site of prostate cancer metastasis, which often results in osteoblastic lesions. The role of transforming growth factor-beta (TGFβ) signaling in prostate cancer-induced osteoblastic metastasis is not clear. We investigated the role of TGFβ signaling in prostate cancer-induced bone metastasis using a novel human prostate cancer cell line, PacMetUT1. METHODS We injected PacMetUT1/Luc-GFP cells in male nude mice by intracardiac and intratibia injections and then investigated the effect of TGFβ signaling abrogation on osteoblastic tumor growth and incidence in vivo by using fluorescence and bioluminescence imaging analysis and quantifying bone and tumor volume by histomorphometry analysis. Osteoclasts were counted using TRAP assay. RESULTS Osteoblastic bone metastasis in skull, rib, and femur was detected after 10-16 weeks of intracardiac injection of the PacMetUT1 cells. Stable knockdown of TGFβ1 with an shRNA resulted in decreased tumor incidence and bone formation when the cells were directly injected into the tibiae. Systemic administration of either a small inhibitor of TGFβ type I receptor kinase or a pan TGFβ binding protein (BGERII) also decreased bone tumor growth and osteoblastic bone formation in vivo after 7 weeks of treatment. CONCLUSIONS Our results for the first time indicate that blockade of TGFβ signaling in the PacMetUT1 model significantly inhibits osteoblastic bone formation and tumor incidence. Thus, TGFβ signaling pathway may be a viable target for the prevention and treatment of prostate cancer-induced bone metastasis.

Original languageEnglish (US)
Pages (from-to)1441-1454
Number of pages14
JournalProstate
Volume71
Issue number13
DOIs
StatePublished - Sep 15 2011

Fingerprint

Transforming Growth Factor beta
Prostatic Neoplasms
Carcinogenesis
Cell Line
Neoplasm Metastasis
Osteogenesis
Bone Neoplasms
Neoplasms
Incidence
Bone and Bones
Injections
Optical Imaging
Bone Development
Ribs
Osteoclasts
Tumor Burden
Tibia
Skull
Nude Mice
Skeleton

Keywords

  • BGRII
  • metastasis
  • osteoblastic lesion
  • osteoclasts
  • TβRI kinase inhibitor

ASJC Scopus subject areas

  • Urology
  • Oncology

Cite this

Blockade of transforming growth factor-beta (TGFβ) signaling inhibits osteoblastic tumorigenesis by a novel human prostate cancer cell line. / Mishra, Sweta; Tang, Yuping; Wang, Long; Degraffenried, Linda; Yeh, I. Tien; Werner, Sherry; Troyer, Dean; Copland, John A III; Sun, Lu Zhe.

In: Prostate, Vol. 71, No. 13, 15.09.2011, p. 1441-1454.

Research output: Contribution to journalArticle

Mishra, Sweta ; Tang, Yuping ; Wang, Long ; Degraffenried, Linda ; Yeh, I. Tien ; Werner, Sherry ; Troyer, Dean ; Copland, John A III ; Sun, Lu Zhe. / Blockade of transforming growth factor-beta (TGFβ) signaling inhibits osteoblastic tumorigenesis by a novel human prostate cancer cell line. In: Prostate. 2011 ; Vol. 71, No. 13. pp. 1441-1454.
@article{a513b3de85c94fa7966f8acb0542b22c,
title = "Blockade of transforming growth factor-beta (TGFβ) signaling inhibits osteoblastic tumorigenesis by a novel human prostate cancer cell line",
abstract = "BACKGROUND The skeleton is the most common site of prostate cancer metastasis, which often results in osteoblastic lesions. The role of transforming growth factor-beta (TGFβ) signaling in prostate cancer-induced osteoblastic metastasis is not clear. We investigated the role of TGFβ signaling in prostate cancer-induced bone metastasis using a novel human prostate cancer cell line, PacMetUT1. METHODS We injected PacMetUT1/Luc-GFP cells in male nude mice by intracardiac and intratibia injections and then investigated the effect of TGFβ signaling abrogation on osteoblastic tumor growth and incidence in vivo by using fluorescence and bioluminescence imaging analysis and quantifying bone and tumor volume by histomorphometry analysis. Osteoclasts were counted using TRAP assay. RESULTS Osteoblastic bone metastasis in skull, rib, and femur was detected after 10-16 weeks of intracardiac injection of the PacMetUT1 cells. Stable knockdown of TGFβ1 with an shRNA resulted in decreased tumor incidence and bone formation when the cells were directly injected into the tibiae. Systemic administration of either a small inhibitor of TGFβ type I receptor kinase or a pan TGFβ binding protein (BGERII) also decreased bone tumor growth and osteoblastic bone formation in vivo after 7 weeks of treatment. CONCLUSIONS Our results for the first time indicate that blockade of TGFβ signaling in the PacMetUT1 model significantly inhibits osteoblastic bone formation and tumor incidence. Thus, TGFβ signaling pathway may be a viable target for the prevention and treatment of prostate cancer-induced bone metastasis.",
keywords = "BGRII, metastasis, osteoblastic lesion, osteoclasts, TβRI kinase inhibitor",
author = "Sweta Mishra and Yuping Tang and Long Wang and Linda Degraffenried and Yeh, {I. Tien} and Sherry Werner and Dean Troyer and Copland, {John A III} and Sun, {Lu Zhe}",
year = "2011",
month = "9",
day = "15",
doi = "10.1002/pros.21361",
language = "English (US)",
volume = "71",
pages = "1441--1454",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "13",

}

TY - JOUR

T1 - Blockade of transforming growth factor-beta (TGFβ) signaling inhibits osteoblastic tumorigenesis by a novel human prostate cancer cell line

AU - Mishra, Sweta

AU - Tang, Yuping

AU - Wang, Long

AU - Degraffenried, Linda

AU - Yeh, I. Tien

AU - Werner, Sherry

AU - Troyer, Dean

AU - Copland, John A III

AU - Sun, Lu Zhe

PY - 2011/9/15

Y1 - 2011/9/15

N2 - BACKGROUND The skeleton is the most common site of prostate cancer metastasis, which often results in osteoblastic lesions. The role of transforming growth factor-beta (TGFβ) signaling in prostate cancer-induced osteoblastic metastasis is not clear. We investigated the role of TGFβ signaling in prostate cancer-induced bone metastasis using a novel human prostate cancer cell line, PacMetUT1. METHODS We injected PacMetUT1/Luc-GFP cells in male nude mice by intracardiac and intratibia injections and then investigated the effect of TGFβ signaling abrogation on osteoblastic tumor growth and incidence in vivo by using fluorescence and bioluminescence imaging analysis and quantifying bone and tumor volume by histomorphometry analysis. Osteoclasts were counted using TRAP assay. RESULTS Osteoblastic bone metastasis in skull, rib, and femur was detected after 10-16 weeks of intracardiac injection of the PacMetUT1 cells. Stable knockdown of TGFβ1 with an shRNA resulted in decreased tumor incidence and bone formation when the cells were directly injected into the tibiae. Systemic administration of either a small inhibitor of TGFβ type I receptor kinase or a pan TGFβ binding protein (BGERII) also decreased bone tumor growth and osteoblastic bone formation in vivo after 7 weeks of treatment. CONCLUSIONS Our results for the first time indicate that blockade of TGFβ signaling in the PacMetUT1 model significantly inhibits osteoblastic bone formation and tumor incidence. Thus, TGFβ signaling pathway may be a viable target for the prevention and treatment of prostate cancer-induced bone metastasis.

AB - BACKGROUND The skeleton is the most common site of prostate cancer metastasis, which often results in osteoblastic lesions. The role of transforming growth factor-beta (TGFβ) signaling in prostate cancer-induced osteoblastic metastasis is not clear. We investigated the role of TGFβ signaling in prostate cancer-induced bone metastasis using a novel human prostate cancer cell line, PacMetUT1. METHODS We injected PacMetUT1/Luc-GFP cells in male nude mice by intracardiac and intratibia injections and then investigated the effect of TGFβ signaling abrogation on osteoblastic tumor growth and incidence in vivo by using fluorescence and bioluminescence imaging analysis and quantifying bone and tumor volume by histomorphometry analysis. Osteoclasts were counted using TRAP assay. RESULTS Osteoblastic bone metastasis in skull, rib, and femur was detected after 10-16 weeks of intracardiac injection of the PacMetUT1 cells. Stable knockdown of TGFβ1 with an shRNA resulted in decreased tumor incidence and bone formation when the cells were directly injected into the tibiae. Systemic administration of either a small inhibitor of TGFβ type I receptor kinase or a pan TGFβ binding protein (BGERII) also decreased bone tumor growth and osteoblastic bone formation in vivo after 7 weeks of treatment. CONCLUSIONS Our results for the first time indicate that blockade of TGFβ signaling in the PacMetUT1 model significantly inhibits osteoblastic bone formation and tumor incidence. Thus, TGFβ signaling pathway may be a viable target for the prevention and treatment of prostate cancer-induced bone metastasis.

KW - BGRII

KW - metastasis

KW - osteoblastic lesion

KW - osteoclasts

KW - TβRI kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=79961038278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961038278&partnerID=8YFLogxK

U2 - 10.1002/pros.21361

DO - 10.1002/pros.21361

M3 - Article

C2 - 21321980

AN - SCOPUS:79961038278

VL - 71

SP - 1441

EP - 1454

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 13

ER -